RU93052411A - (-) - ENANTIOMER - {([4- (1,4,5,6-TETRAGIDRO-4-METHYL-6-OXO-3-PYRIDAZINYL) PHENYL]) - HYDRAZONE} PROPANDININITRIL - Google Patents

(-) - ENANTIOMER - {([4- (1,4,5,6-TETRAGIDRO-4-METHYL-6-OXO-3-PYRIDAZINYL) PHENYL]) - HYDRAZONE} PROPANDININITRIL

Info

Publication number
RU93052411A
RU93052411A RU93052411/04A RU93052411A RU93052411A RU 93052411 A RU93052411 A RU 93052411A RU 93052411/04 A RU93052411/04 A RU 93052411/04A RU 93052411 A RU93052411 A RU 93052411A RU 93052411 A RU93052411 A RU 93052411A
Authority
RU
Russia
Prior art keywords
pyridazinyl
enantiomer
oxo
phenyl
methyl
Prior art date
Application number
RU93052411/04A
Other languages
Russian (ru)
Other versions
RU2118317C1 (en
Inventor
Норе Пентти
Хонканен Эркки
Бяккстрем Рейьо
Викберг Том
Хайкала Хеймо
Харала Йорма
Original Assignee
Орион-Ихтюмя Ой
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919100049A external-priority patent/GB9100049D0/en
Priority claimed from GB919118947A external-priority patent/GB9118947D0/en
Application filed by Орион-Ихтюмя Ой filed Critical Орион-Ихтюмя Ой
Publication of RU93052411A publication Critical patent/RU93052411A/en
Application granted granted Critical
Publication of RU2118317C1 publication Critical patent/RU2118317C1/en

Links

Claims (1)

Изобретение относится к оптически значительно чистому (-)= энантиомеру {[4=(1,4,5,6-тетрагидро-4-метил-6-оксо-3-пиридазинил)фенил)] гидразоно}пропандинитрила или его фармацевтически приемлемой соли промежуточным соединениям и способу их получения. Продукт полезен в качестве кардиотонического средства, антигипертензивного и вазодилаторного средства для печения застойной сердечной недостаточности.The invention relates to the optically significantly pure (-) = enantiomer {[4 = (1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl) phenyl)] hydrazono} propanedinitrile or its pharmaceutically acceptable salt intermediate compounds and their preparation. The product is useful as a cardiotonic agent, antihypertensive and vasodilator agent for baking congestive heart failure.
RU93052411A 1991-01-03 1992-01-03 (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phen- -yl]hydrozono]propanedinitrile and its pharmaceutically acceptable salts, pharmaceutical composition based on thereof, method of synthesis of intermediate compound and method of synthesis of end compound RU2118317C1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9100049.7 1991-01-03
GB919100049A GB9100049D0 (en) 1991-01-03 1991-01-03 (-)-6-(4-(dicyanomethylidenehydrazino)phenyl)-4,5-dihydro-5-methylpyridazin-3(2h)one
GB919118947A GB9118947D0 (en) 1991-09-05 1991-09-05 Method for the optical resolution of racemic 6-(4-amino-phenyl)-methyl-pyridazin-3(2h)one and preparation of optically active derivatives thereof
GB9118947.2 1991-09-05

Publications (2)

Publication Number Publication Date
RU93052411A true RU93052411A (en) 1996-06-20
RU2118317C1 RU2118317C1 (en) 1998-08-27

Family

ID=26298204

Family Applications (1)

Application Number Title Priority Date Filing Date
RU93052411A RU2118317C1 (en) 1991-01-03 1992-01-03 (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phen- -yl]hydrozono]propanedinitrile and its pharmaceutically acceptable salts, pharmaceutical composition based on thereof, method of synthesis of intermediate compound and method of synthesis of end compound

Country Status (32)

Country Link
US (3) US5424428A (en)
EP (1) EP0565546B1 (en)
JP (2) JP2635445B2 (en)
KR (1) KR100207145B1 (en)
AT (1) ATE119525T1 (en)
AU (1) AU645399B2 (en)
BG (1) BG62002B1 (en)
BR (1) BR1100737A (en)
CA (2) CA2314115C (en)
CY (1) CY1878A (en)
DE (1) DE69201640T2 (en)
DK (1) DK0565546T3 (en)
EE (1) EE02946B1 (en)
ES (1) ES2070627T3 (en)
FI (1) FI105183B (en)
GB (1) GB2251615B (en)
GE (1) GEP19991868B (en)
HK (1) HK117395A (en)
HR (1) HRP921251B1 (en)
HU (1) HU218659B (en)
IE (1) IE72101B1 (en)
IL (2) IL114028A (en)
LU (1) LU90920I2 (en)
LV (1) LV11174B (en)
NO (2) NO300682B1 (en)
NZ (1) NZ241194A (en)
PL (2) PL169415B1 (en)
RO (1) RO111847B1 (en)
RU (1) RU2118317C1 (en)
SI (1) SI9112003A (en)
WO (1) WO1992012135A1 (en)
YU (1) YU48767B (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2251615B (en) * 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
GB2266841A (en) * 1992-05-06 1993-11-17 Orion Yhtymae Oy Compounds for use as anti-ischemic medicaments
JP2806192B2 (en) * 1992-11-02 1998-09-30 日本曹達株式会社 Platelet aggregation inhibitor
EP0791584A4 (en) * 1994-11-11 1997-11-19 Nippon Soda Co Optically active compound
GB9606474D0 (en) * 1996-03-27 1996-06-05 Orion Yhytmo Oy Method for obtaining pure enantiomers of a pyridazinone derivative
GB9614098D0 (en) 1996-07-05 1996-09-04 Orion Yhtymae Oy Transdermal delivery of levosimendan
FI973804A (en) * 1997-09-26 1999-03-27 Orion Yhtymae Oy Oral compositions of levosimendan
FI974578A (en) * 1997-12-19 1999-06-20 Orion Yhtymae Oyj Method of administering levosimendan
FI980902A (en) * 1998-04-23 1999-10-24 Orion Yhtymae Oyj Stable compositions of levosimendan
FI980901A (en) * 1998-04-23 1999-10-24 Orion Yhtymae Oyj Oral compositions that controlled release the levosimendan
FI104718B (en) * 1998-06-18 2000-03-31 Orion Yhtymae Oyj [[4- (2-Azido-3-methyl-5-oxotetrahydrofuran-2-yl) phenyl] hydrazono] propanedonitrile for use as reference substance in the analysis of batches of levosimendan
US5905078A (en) * 1998-06-19 1999-05-18 Orion Corporation Use of a pyridazinone derivative
FI981473A (en) * 1998-06-25 1999-12-26 Orion Yhtymae Oyj A method of treating pulmonary hypertension
GB9915179D0 (en) * 1999-06-29 1999-09-01 Orion Corp A method for the treatment or prevention of coronary graft vasospasm
FI109659B (en) 1999-09-10 2002-09-30 Orion Yhtymae Oyj Pharmaceutical solutions of levosimendan
EP1248620B1 (en) * 1999-10-22 2004-11-17 Orion Corporation A new use of levosimendan
FI20001542A (en) * 2000-06-29 2001-12-30 Orion Yhtymae Oyj A method of treating septic shock
FI20002526A (en) * 2000-11-17 2002-05-18 Orion Yhtymae Oyj New use of pyridazinone derivatives
FI20002525A (en) 2000-11-17 2002-05-18 Orion Yhtymae Oyj Anti-inflammatory substances
FI20002755A0 (en) 2000-12-15 2000-12-15 Orion Yhtymae Oyj Method of therapy for erectile dysfunction
FI20010233A0 (en) 2001-02-08 2001-02-08 Orion Corp A method for treating heart failure
FI20011464A0 (en) 2001-07-04 2001-07-04 Orion Corp Combination therapy for the treatment of heart failure
FI20030015A0 (en) * 2003-01-03 2003-01-03 Orion Corp A method of treating renal failure
CA2521056A1 (en) * 2003-03-31 2004-10-14 Daiichi Pharmaceutical Co., Ltd. Hydrazone derivative
DE102004011512B4 (en) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical preparation containing pimobendan
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) * 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
FI20040674A0 (en) 2004-05-12 2004-05-12 Orion Corp A method of inhibiting thromboembolic diseases
FI20040675A0 (en) * 2004-05-12 2004-05-12 Orion Corp A method of treating and preventing cardiac hypertrophy
CA2568393A1 (en) * 2004-05-28 2005-12-15 Abbott Laboratories Methods for treating a mammal before, during and after cardiac arrest
JP2008533109A (en) 2005-03-14 2008-08-21 オリオン コーポレーション Combined therapy to promote diuresis
EP3210605A1 (en) 2005-11-14 2017-08-30 Boehringer Ingelheim Vetmedica GmbH Use of pde iii inhibitors for the treament of asymptomatic (occult) heart failure
EP1920785A1 (en) * 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
EP2117551A1 (en) * 2007-01-17 2009-11-18 Orion Corporation Levosimendan for use in treating chronic valvular disease
PT2370070E (en) 2008-11-25 2013-11-18 Boehringer Ingelheim Vetmed Pimobendan for use in the treatment of hypertrophic cardiomyopathy in cats.
AU2010272364B2 (en) 2009-07-14 2014-04-10 Cipla Limited Process for preparing levosimendan and intermediates for use in the process
ES2924478T3 (en) 2012-03-15 2022-10-07 Boehringer Ingelheim Vetmedica Gmbh Formulation of pharmaceutical tablets for the veterinary medical sector, method of production and use thereof
WO2014164704A2 (en) * 2013-03-11 2014-10-09 The Broad Institute, Inc. Compounds and compositions for the treatment of cancer
CN113181110A (en) 2013-07-19 2021-07-30 勃林格殷格翰动物保健有限公司 Liquid aqueous pharmaceutical composition containing preserved etherified cyclodextrin derivatives
CN104418810A (en) * 2013-09-04 2015-03-18 北京博时安泰科技发展有限公司 New synthetic route of levosimendan
CN103554032A (en) * 2013-11-12 2014-02-05 江苏正大清江制药有限公司 Preparation method of high-optical-purity (-)-6-(4-aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone
CN103554033A (en) * 2013-11-12 2014-02-05 江苏正大清江制药有限公司 Splitting method for despinner (+/-)-6-(4-aminophenyl)-4, 5-dihydro-5-methyl-3(2H)-pyridazinone
WO2015082389A1 (en) 2013-12-04 2015-06-11 Boehringer Ingelheim Vetmedica Gmbh Improved pharmaceutical compositions of pimobendan
US11207320B2 (en) 2015-08-13 2021-12-28 The Broad Institute, Inc. Compositions and methods for cancer expressing PDE3A or SLFN12
CN105784895B (en) * 2015-10-30 2018-05-22 成都欣捷高新技术开发有限公司 A kind of method that impurity in Levosimendan is detected with high performance liquid chromatograph
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
EP3424908A1 (en) 2017-07-07 2019-01-09 Melody Healthcare Pvt. Ltd. Process for preparation of levosimendan
US9962384B1 (en) * 2017-09-07 2018-05-08 Korea Institute Of Science And Technology Levosimendan compound for preventing or treating tau-related diseases
CN111548310B (en) * 2020-05-12 2021-07-02 成都欣捷高新技术开发股份有限公司 Levosimendan sodium crystal form and preparation method thereof
CN111718299B (en) * 2020-07-23 2023-03-10 成都欣捷高新技术开发股份有限公司 Levosimendan sodium crystal form B and preparation method thereof
US11760730B2 (en) 2021-01-11 2023-09-19 Navinta, Llc Process for the preparation of high purity Levosimendan

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB228004A (en) * 1924-01-24 1925-01-29 Daimler Co Ltd Improvements in locking devices for sliding windows
JPS58113180A (en) * 1981-12-28 1983-07-05 Mitsui Toatsu Chem Inc Pyridazinone derivative
JPS6193169A (en) * 1984-10-12 1986-05-12 Sankyo Co Ltd Pyridazinone derivative and its preparation
AU581324B2 (en) * 1985-07-05 1989-02-16 Smith Kline & French Laboratories Limited Substituted 6-phenyl-4,5-dihydro pyradazin-3-ones
JPH0629254B2 (en) * 1986-09-08 1994-04-20 帝国臓器製薬株式会社 Pyridazinone derivative
GB8824458D0 (en) * 1988-10-19 1988-11-23 Orion Yhtymae Oy Substituted pyridazinones
GB8903130D0 (en) * 1989-02-11 1989-03-30 Orion Yhtymae Oy Substituted pyridazinones
GB2251615B (en) * 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile

Similar Documents

Publication Publication Date Title
RU93052411A (en) (-) - ENANTIOMER - {([4- (1,4,5,6-TETRAGIDRO-4-METHYL-6-OXO-3-PYRIDAZINYL) PHENYL]) - HYDRAZONE} PROPANDININITRIL
CA2099262A1 (en) (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl) phenyl]hydrazono]propanedinitrile
CA2134972A1 (en) Anti-ischemic medicament
EP0168262A3 (en) Pyrimidine derivatives, processes for preparation thereof and use thereof
CA2075173A1 (en) Compounds and methods for inhibition of hiv and related viruses
HK21595A (en) Use of 1-(3-dimethyl-amino)propyl)-1-phenylphthalenes for the treatment of cerebrovascular disorders
EP0121830A3 (en) Substituted dipeptides as antihypertensives
CA2182477A1 (en) Pyridyl Imidazole Derivatives and Processes for the Preparation Thereof
EP0201349A3 (en) Tetrazole derivatives
EP0180542A3 (en) alkyl substituted pyridazinones, processes for producing them, pharmaceutical preparations containing these compounds, and the use thereof
EE04355B1 (en) Use of levosimendan in the manufacture of a medicament for pulmonary hypertension
JPS5697226A (en) Blood platelet coagulation inhibitor
AU6713887A (en) Methionine-substituted 1, 4-dihydropyridines, process for the preparation and their use
ATE151987T1 (en) USE OF 3-PYRIDAZINONE TO REDUCE PLATELE COUNTS
WO1995008989B1 (en) Endothelin antagonists incorporating a cyclobutane
MY104782A (en) Glutaric acid derivatives and preparations thereof.
EP0127090A3 (en) Angiotensin-converting enzyme inhibitors